Companies / Engimmune Therapeutics
Engimmune Therapeutics
Company
Engimmune Therapeutics develops targeted, highly potent 'off-the-shelf' soluble T-cell receptor drugs to treat solid tumour cancers.
Engimmune Therapeutics has 1 investor on file, among them Pureos Bioventures. Its site was last checked 6 Nov 2026: site answers.
Investors
1 investor on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital |
More from Pureos Bioventures
21 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (100%).
See Pureos Bioventures' full profile · Who invests alongside it
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Engimmune Therapeutics and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Pureos Bioventures adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/engimmune.com/investors
# also
GET /v1/companies/engimmune.com
GET /v1/companies/engimmune.com/news